Yu Ke-Da相关文献与解析，生知库 | 链接生命科学的每一步

CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer

CD8 靶向免疫化疗可提高高肿瘤负荷三阴性乳腺癌的病理完全缓解率

doi:10.1016/j.ymthe.2025.10.056

Chen, Li; Jiang, Shu-Hao; Liu, Guang-Yu; Yu, Ke-Da; Wu, Jiong; Di, Gen-Hong; Zhang, Wen-Juan; Ma, Lin-Xiaoxi; Liang, Qian-Nan; Shen, Yu; Wang, Zhong-Hua; Shao, Zhi-Ming; Li, Jun-Jie

Breast cancer: pathogenesis and treatments

乳腺癌：发病机制和治疗

期刊:Signal Transduction and Targeted Therapy

影响因子:52.7

doi:10.1038/s41392-024-02108-4

Xiong, Xin; Zheng, Le-Wei; Ding, Yu; Chen, Yu-Fei; Cai, Yu-Wen; Wang, Lei-Ping; Huang, Liang; Liu, Cui-Cui; Shao, Zhi-Ming; Yu, Ke-Da

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial

卡铂强化辅助化疗与标准化疗对高危早期三阴性乳腺癌女性患者生存率的影响（CITRINE）：一项随机、开放标签的3期临床试验

期刊:Bmj-British Medical Journal

影响因子:42.7

doi:10.1136/bmj-2025-085457

Liu, Yin; Gong, Yue; Zhu, Xiu-Zhi; Liu, Guang-Yu; Yu, Ke-Da; Yang, Fan; Chen, Li; He, Min; Hu, Zhen; Chen, Can-Ming; Cao, A-Yong; Li, Jun-Jie; Hou, Yi-Feng; Di, Gen-Hong; Wu, Jiong; Jiang, Yi-Zhou; Fan, Lei; Wang, Zhong-Hua; Shao, Zhi-Ming

Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)

Sitravatinib 联合 tislelizumab 治疗局部复发或转移性三阴性乳腺癌：一项多队列、单臂 II 期临床试验（SPARK 试验）

期刊:Molecular Cancer

影响因子:33.9

doi:10.1186/s12943-025-02505-5

Liu, Xi-Yu; Sui, Xin-Yi; Xu, Ying; Yang, Fan; Wu, Song-Yang; Zhu, Xiu-Zhi; Zuo, Ke; Cao, Shuo-Wen; Jin, Xi; Chen, Li; Ma, Lin-Xiaoxi; Zhang, Wen-Juan; Ye, Fu-Gui; Qu, Fei-Lin; Ma, Ding; Xiao, Yi; Di, Gen-Hong; Liu, Guang-Yu; Yu, Ke-Da; Wu, Jiong; Hu, Xin; Jiang, Yi-Zhou; Wang, Zhong-Hua; Shao, Zhi-Ming; Fan, Lei

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study

一项基于化疗敏感性的前瞻性 II 期新辅助治疗研究——FINEST 研究（HR+/HER2- 乳腺癌）。

期刊:Cancer Communications

影响因子:24.9

doi:10.1002/cac2.12649

Chen, Li; Wu, Wen-Ya; Liang, Fei; Liu, Guang-Yu; Yu, Ke-Da; Wu, Jiong; Di, Gen-Hong; Fan, Lei; Wang, Zhong-Hua; Li, Jun-Jie; Shao, Zhi-Ming

RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond

肿瘤微环境中的RNA修饰：对癌症-免疫循环及其他方面的深入理解

期刊:Experimental Hematology & Oncology

影响因子:13.5

doi:10.1186/s40164-025-00648-1

Ding, You-Peng; Liu, Cui-Cui; Yu, Ke-Da

SNX10 deficiency impairs sensitivity to anti-HER2 antibody-drug conjugates via altering HER2 trafficking in HER2-positive breast cancer.

SNX10 缺乏会通过改变 HER2 阳性乳腺癌中 HER2 的转运来降低对 HER2 抗体药物偶联物的敏感性

期刊:Proceedings of the National Academy of Sciences of the United States of America

影响因子:9.1

doi:10.1073/pnas.2417586122

Chen Yu-Fei, Zhang Qing-Hua, Zhang Zhong-Wei, Zhou Yu-Jie, Liu Cui-Cui, Shao Zhi-Ming, Yu Ke-Da

Immunotherapy and its racial specificity for breast cancer treatment in Asia: a narrative review

亚洲乳腺癌治疗中免疫疗法及其种族特异性：叙述性综述

期刊:The Lancet Regional Health Western Pacific

影响因子:8.1

doi:10.1016/j.lanwpc.2024.101180

Xu, Rui-Chen; Zhang, Yan-Wu; Liu, Cui-Cui; Xu, Ying-Ying; Shao, Zhi-Ming; Yu, Ke-Da

Artificial intelligence-based diagnosis of breast cancer by mammography microcalcification

基于人工智能的乳腺癌微钙化诊断

期刊:Fundamental Research

影响因子:6.3

doi:10.1016/j.fmre.2023.04.018

Lin, Qing; Tan, Wei-Min; Ge, Jing-Yu; Huang, Yan; Xiao, Qin; Xu, Ying-Ying; Jin, Yi-Ting; Shao, Zhi-Ming; Gu, Ya-Jia; Yan, Bo; Yu, Ke-Da

Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities

癌症基因组不稳定性的代谢驱动因素：机制和治疗机遇

CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer

CD8 靶向免疫化疗可提高高肿瘤负荷三阴性乳腺癌的病理完全缓解率

Breast cancer: pathogenesis and treatments

乳腺癌：发病机制和治疗

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial

卡铂强化辅助化疗与标准化疗对高危早期三阴性乳腺癌女性患者生存率的影响（CITRINE）：一项随机、开放标签的3期临床试验

Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)

Sitravatinib 联合 tislelizumab 治疗局部复发或转移性三阴性乳腺癌：一项多队列、单臂 II 期临床试验（SPARK 试验）

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study

一项基于化疗敏感性的前瞻性 II 期新辅助治疗研究——FINEST 研究（HR+/HER2- 乳腺癌）。

RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond

肿瘤微环境中的RNA修饰：对癌症-免疫循环及其他方面的深入理解

SNX10 deficiency impairs sensitivity to anti-HER2 antibody-drug conjugates via altering HER2 trafficking in HER2-positive breast cancer.

SNX10 缺乏会通过改变 HER2 阳性乳腺癌中 HER2 的转运来降低对 HER2 抗体药物偶联物的敏感性

Immunotherapy and its racial specificity for breast cancer treatment in Asia: a narrative review

亚洲乳腺癌治疗中免疫疗法及其种族特异性：叙述性综述

Artificial intelligence-based diagnosis of breast cancer by mammography microcalcification

基于人工智能的乳腺癌微钙化诊断